GlobeNewswire

HAProxy Technologies Announces Improvements to Performance, Management, and Security for Enterprises

Dela

HAProxy Enterprise Edition 1.8r1 Adds HTTP/2, Dynamic Scaling, WAF, and Other Key Enterprise Features

BOSTON, May 02, 2018 (GLOBE NEWSWIRE) -- HAProxy Technologies, the company behind the world's fastest and most widely used software load balancer, is announcing the release of HAProxy  Enterprise Edition 1.8r1. HAProxy Enterprise Edition 1.8r1 is built on top of the monumental stable release of HAProxy 1.8 with additional enhancements that help enterprises manage and secure modern application environments across the full spectrum of today's threats.

HAProxy Enterprise Edition 1.8r1 contains a number of powerful improvements in performance and application acceleration such as support for HTTP/2, Multithreading, and Small Object Caching. There are also significant improvements in dynamic capabilities for cloud and microservices environments including Hitless Reloads, DNS for Service Discovery, Server Templates, and improved Runtime API functionality.

"This is the biggest and possibly most anticipated release of HAProxy Enterprise Edition we have ever had," said Willy Tarreau, CTO HAProxy Technologies. "I'm very proud of the whole HAProxy Technologies R&D team as well as the community contributors for their hard work in advancing HAProxy in multiple key areas including fast and secure edge and microservices delivery, while maintaining the proven reliability that it is known for."

HAProxy Enterprise Edition 1.8r1 ships with an enterprise suite which contains administration and security-focused add-ons that have the same level of high performance that users expect from HAProxy. The latest additions include a new Web Application Firewall, Stick Table Aggregator with real time, cluster-wide tracking for improved DDoS attack and bot protection, direct integration with Google reCAPTCHA, Single Sign On (SSO) support, and significant improvements to the Real Time Dashboard.

"As the company behind the world's fastest and most widely used software load balancer, we have been trusted by millions of websites to continually deliver highly secure and reliable products," said Dujko Radovnikovic, CEO HAProxy Technologies. "Our latest release strengthens this trust by providing a powerful set of new features to manage and secure modern applications while maintaining our best-in-class performance and reliability."

"We initially chose HAProxy Enterprise Edition over other software load balancers due to its performance and reliability. Since then we've worked closely with the HAProxy Technologies team to provide feedback and leverage their support. We are very excited to see the 1.8r1 release which not only includes many useful capabilities, but also incorporates many of our own feature requests," said Scott Bruce, Director of Application Architecture, dataxu.

HAProxy 1.8 and HAProxy Enterprise Edition 1.8r1 Key Enhancements:

  • HTTP/2 Support - Support for clients to communicate with the load balancer via the HTTP/2 protocol.

  • Multithreading - Splits processing across multiple threads while sharing the same memory space.

  • HTTP Small Object Caching - Caches small objects in memory.

  • Hitless Reloads - Reloads of HAProxy do not lose any connections for upgrades or changes to the configuration.

  • DNS for Service Discovery - Dynamically scales the number of backend servers by querying the service registry over DNS. Maintains the IP address, port, and weight of the servers within HAProxy.

  • Server Templates - Enables the provisioning of multiple backend servers with a single server line to be filled in during runtime.

  • Improved Runtime API - Gives the ability to pull statistics and information from HAProxy or to dynamically configure it during runtime.

Exclusive HAProxy Enterprise Edition 1.8r1 Key Enhancements:

  • WAF Module - A high-performance Web Application Firewall which supports both whitelist based and blacklist based rulesets, ensuring a very high level of protection for even the most insecure web applications.

  • Stick Table Aggregator - Combines values from stick tables across multiple processes or servers which allows for real time cluster-wide tracking of any characteristic of a request.

  • reCAPTCHA Module - Enables presenting anomalous clients with Google reCAPTCHA v2 challenges which can protect websites from bots and other types of automated threats while letting real users pass through with ease.

  • SSO Module - Enables the implementation of SSO (Single Sign On) on a Microsoft Active Directory domain.

  • Real Time Dashboard - Provides management capabilities and an aggregated view of service activity and status which updates and graphs in real time, with visual alerting when values reach defined thresholds.

For more information on everything new in HAProxy Enterprise Edition 1.8r1, you can watch the on-demand webinar at What's New in HAProxy Enterprise Edition 1.8r1

About HAProxy Enterprise Edition

HAProxy Enterprise Edition is an enterprise-class version of HAProxy that includes a robust and cutting-edge code base, enterprise suite of add-ons, expert support, and professional services. At its core, it incorporates feature backports from the HAProxy development branch for customers who require immediate access to the latest functionality in a hardened version of code.

About HAProxy Technologies

HAProxy Technologies is the company behind HAProxy, the world's fastest and most widely used software load balancer. High-profile websites including Booking.com, GitHub, Reddit, StackOverflow, Tumblr, Vimeo and Yelp choose HAProxy to deliver websites and applications with high availability, performance, and security at any scale. Trusted by leading cloud providers such as Amazon Web Services, Rackspace, Red Hat OpenShift, and OpenStack, HAProxy sets the standard for superior application delivery. HAProxy Technologies is headquartered in Waltham, MA, with offices in France and Croatia. For more information on HAProxy, support, and enterprise solutions, visit: www.haproxy.com. You can also follow @HAProxy on Twitter or visit us on LinkedIn and Facebook for more information about HAProxy.

Media Contact

Company Name: HAProxy Technologies
Email Address: press@haproxy.com Website: www.haproxy.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: HAProxy Technologies via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum